Inhibitors of VEGF receptor and HGF receptor signaling
View Patent ↗The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
1. A compound selected from the group consisting of
and pharmaceutically acceptable salts thereof.
2. A compound selected from the group consisting of
and pharmaceutically acceptable salts thereof.
3. A compound selected from the group consisting of
and pharmaceutically acceptable salts thereof.
4. A compound selected from the group consisting of
and pharmaceutically acceptable salts thereof.
5. A compound selected from the group consisting of
and pharmaceutically acceptable salts thereof.
6. A compound selected from the group consisting of
and pharmaceutically acceptable salts thereof.
7. The compound according to claim 1 , having the structure
8. The compound according to claim 1 , having the structure
9. The compound according to claim 1 , having the structure
10. The compound according to claim 1 , having the structure
11. The compound according to claim 1 , having the structure
12. The compound according to claim 1 , having the structure
13. The compound according to claim 1 , having the structure
14. The compound according to claim 1 , having the structure
15. The compound according to claim 1 , having the structure
16. The compound according to claim 1 , having the structure
17. The compound according to claim 1 , having the structure
18. The compound according to claim 2 , having the structure
19. The compound according to claim 3 , having the structure
20. The compound according to claim 3 , having the structure
21. The compound according to claim 3 , having the structure
22. The compound according to claim 3 , having the structure
23. The compound according to claim 3 , having the structure
24. The compound according to claim 5 , having the structure
25. The compound according to claim 5 , having the structure
26. The compound according to claim 5 , having the structure
27. The compound according to claim 6 , having the structure
28. The compound according to claim 6 , having the structure
29. The compound according to claim 6 , having the structure
30. The compound according to claim 6 , having the structure
31. The compound according to claim 6 , having the structure
32. An N-oxide of a compound according to claim 1 .
33. An N-oxide of a compound according to claim 2 .
34. An N-oxide of a compound according to claim 3 .
35. An N-oxide of a compound according to claim 4 .
36. An N-oxide of a compound according to claim 5 .
37. An N-oxide of a compound according to claim 6 .
38. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
39. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier.
40. A pharmaceutical composition comprising a compound according to claim 3 and a pharmaceutically acceptable carrier.
41. A pharmaceutical composition comprising a compound according to claim 4 and a pharmaceutically acceptable carrier.
42. A pharmaceutical composition comprising a compound according to claim 5 and a pharmaceutically acceptable carrier.
43. A pharmaceutical composition comprising a compound according to claim 6 and a pharmaceutically acceptable carrier.
44. A method of inhibiting VEGF receptor signaling and HGF receptor signaling in an animal, the method comprising administering to the animal a receptor inhibiting amount of a compound according to claim 1 , or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.
45. A method of inhibiting VEGF receptor signaling and HGF receptor signaling in an animal, the method comprising administering to the animal a receptor inhibiting amount of a compound according to claim 2 , or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.
46. A method of inhibiting VEGF receptor signaling and HGF receptor signaling in an animal, the method comprising administering to the animal a receptor inhibiting amount of a compound according to claim 3 , or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.
47. A method of inhibiting VEGF receptor signaling and HGF receptor signaling in an animal, the method comprising administering to the animal a receptor inhibiting amount of a compound according to claim 4 , or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.
48. A method of inhibiting VEGF receptor signaling and HGF receptor signaling in an animal, the method comprising administering to the animal a receptor inhibiting amount of a compound according to claim 5 , or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.
49. A method of inhibiting VEGF receptor signaling and HGF receptor signaling in an animal, the method comprising administering to the animal a receptor inhibiting amount of a compound according to claim 6 , or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.
50. A method of treating an angiogenesis-mediated cell proliferative disease in a patient or inhibiting solid tumor growth in a patient, the method comprising administering to the patient in need thereof an effective therapeutical amount of a compound according to claim 1 or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.
51. A method of treating an angiogenesis-mediated cell proliferative disease in a patient or inhibiting solid tumor growth in a patient, the method comprising administering to the patient in need thereof an effective therapeutical amount of a compound according to claim 2 or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.
52. A method of treating an angiogenesis-mediated cell proliferative disease in a patient or inhibiting solid tumor growth in a patient, the method comprising administering to the patient in need thereof an effective therapeutical amount of a compound according to claim 3 or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.
53. A method of treating an angiogenesis-mediated cell proliferative disease in a patient or inhibiting solid tumor growth in a patient, the method comprising administering to the patient in need thereof an effective therapeutical amount of a compound according to claim 4 or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.
54. A method of treating an angiogenesis-mediated cell proliferative disease in a patient or inhibiting solid tumor growth in a patient, the method comprising administering to the patient in need thereof an effective therapeutical amount of a compound according to claim 5 or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.
55. A method of treating an angiogenesis-mediated cell proliferative disease in a patient or inhibiting solid tumor growth in a patient, the method comprising administering to the patient in need thereof an effective therapeutical amount of a compound according to claim 6 or an N-oxide thereof or a composition comprising said compound or an N-oxide thereof and a pharmaceutically acceptable carrier.